Definitive Healthcare (NASDAQ:DH) Releases FY 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 0.340-0.350 for the period, compared to the consensus earnings per share estimate of 0.330. The company issued revenue guidance of $250.0 million-$251.0 million, compared to the consensus revenue estimate of $249.2 million. Definitive Healthcare also updated its Q4 guidance to $0.07 EPS.

Definitive Healthcare Stock Performance

NASDAQ:DH traded up $0.01 during mid-day trading on Thursday, hitting $4.31. 543,720 shares of the company traded hands, compared to its average volume of 748,693. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.27. The stock’s fifty day moving average price is $4.38 and its 200-day moving average price is $5.04. The firm has a market cap of $508.28 million, a price-to-earnings ratio of -1.24, a price-to-earnings-growth ratio of 5.95 and a beta of 1.33. Definitive Healthcare has a one year low of $3.19 and a one year high of $10.62.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.09. Definitive Healthcare had a positive return on equity of 0.98% and a negative net margin of 156.65%. The company had revenue of $63.70 million during the quarter, compared to the consensus estimate of $63.19 million. During the same period in the previous year, the company posted $0.08 EPS. The firm’s revenue was up 4.4% on a year-over-year basis. Research analysts anticipate that Definitive Healthcare will post 0.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DH. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research note on Tuesday, August 6th. Barclays cut their price target on Definitive Healthcare from $6.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft lowered their price objective on Definitive Healthcare from $7.00 to $5.00 and set a “hold” rating on the stock in a research report on Friday, August 9th. Stifel Nicolaus cut their target price on Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Finally, BTIG Research assumed coverage on Definitive Healthcare in a report on Tuesday, September 17th. They issued a “buy” rating and a $7.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.81.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.